DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia
暂无分享,去创建一个
A. Pettitt | R. Griffin | B. Durkacz | G. Jackson | G. Summerfield | I. Cowell | E. Willmore | C. Austin | C. Cano-Soumillac | R. Harris | A. Carter | T. Mainou-fowler | C. Lowe | Barbara W. Durkacz | Sarah L. Elliott | Elaine Willmore | Tryfonia Mainou-Fowler | Geoffrey P. Summerfield | F. O'Neill | Christopher Lowe | Celine Cano-Soumillac | Ian G. Cowell
[1] A. Pettitt,et al. The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia , 2007, Leukemia.
[2] B. Jean-Claude,et al. Chlorambucil Cytotoxicity in Malignant B Lymphocytes Is Synergistically Increased by 2-(Morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-Mediated Inhibition of DNA Double-Strand Break Repair via Inhibition of DNA-Dependent Protein Kinase , 2007, Journal of Pharmacology and Experimental Therapeutics.
[3] G. Pamuk,et al. 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis , 2007, Leukemia & lymphoma.
[4] N. Curtin,et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. , 2006, Cancer research.
[5] A. Pettitt,et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia , 2006, Leukemia.
[6] M. Tilby,et al. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated. , 2005, Biochemical pharmacology.
[7] T. Stankovic,et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.
[8] N. Curtin,et al. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. , 2005, Journal of medicinal chemistry.
[9] S. Johnson,et al. Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. , 2005, Clinical and laboratory haematology.
[10] M. Ricoul,et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. , 2005, Blood.
[11] P. Jeggo,et al. The life and death of DNA-PK , 2005, Oncogene.
[12] I. Hardcastle,et al. Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. , 2005, Journal of medicinal chemistry.
[13] A. Pettitt,et al. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia , 2004, British journal of haematology.
[14] N. Curtin,et al. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair , 2004, Oncogene.
[15] M. Tilby,et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. , 2004, Blood.
[16] S. Proctor,et al. Quantification of CD38 expression in B-cell chronic lymphocytic leukemia (B-CLL): a comparison between antibody binding capacity (ABC) and relative median fluorescence (RMF). , 2004, Leukemia & lymphoma.
[17] T. Stankovic,et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. , 2004, Blood.
[18] N. K. Sah,et al. Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity. , 2003, Molecular cancer therapeutics.
[19] W. Plunkett,et al. Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] B. Dörken,et al. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy , 2003, Cell Death and Differentiation.
[21] S. Proctor,et al. Quantification improves the prognostic value of CD38 expression in B‐cell chronic lymphocytic leukaemia , 2002, British journal of haematology.
[22] W. Plunkett,et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[24] S. Boulton,et al. Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin. , 2000, European journal of cancer.
[25] C. Muller,et al. The activity of the DNA-dependent protein kinase (DNA-PK) complex is determinant in the cellular response to nitrogen mustards. , 2000, Biochimie.
[26] L. Panasci,et al. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] S. Jackson,et al. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. , 1999, Cancer research.
[28] L. Panasci,et al. Chlorambucil Induction of HsRad 51 in B-Cell Chronic Lymphocytic Leukemia 1 , 1999 .
[29] L. Panasci,et al. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. , 1998, Blood.
[30] K. Rosenzweig,et al. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] K. Lee,et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. , 1997, Leukemia & lymphoma.
[32] D. Murray,et al. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs , 1996, Cancer Chemotherapy and Pharmacology.
[33] K Y Hui,et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.